|Bid||266.17 x 800|
|Ask||277.66 x 800|
|Day's range||269.93 - 279.86|
|52-week range||119.01 - 319.19|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||78.49|
|Earnings date||29 Oct 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||315.40|
Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates. Early identification of patients requiring right-heart support is critical because prior studies have shown 37% of AMI cardiogenic shock (AMICS) patients exhibit right heart dysfunction1, which results in an eight times increased risk of mortality2.
Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation.
New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.